Painful diabetic neuropathy (PDN) is a debilitating consequence of diabetes that may be present in as many as one in five patients with diabetes. The objective assessment of PDN is difficult, making it challenging to diagnose and assess in both clinical practice and clinical trials. No single treatment exists to prevent or reverse neuropathic changes or to provide total pain relief. Treatment of PDN is based on three major approaches: intensive glycaemic control and risk factor management, treatments based on pathogenetic mechanisms, and symptomatic pain management. Clinical guidelines recommend pain relief in PDN through the use of antidepressants such as amitriptyline and duloxetine, the γ-aminobutyric acid analogues gabapentin and pregabalin, opioids and topical agents such as capsaicin. Of these medications, duloxetine and pregabalin were approved by the US Food and Drug Administration (FDA) in 2004 and tapentadol extended release was approved in 2012 for the treatment of PDN. Proposed pathogenetic treatments include α-lipoic acid (stems reactive oxygen species formation), benfotiamine (prevents vascular damage in diabetes) and aldosereductase inhibitors (reduces flux through the polyol pathway). There is a growing need for studies to evaluate the most potent drugs or combinations for the management of PDN to maximize pain relief and improve quality of life. A number of agents are potential candidates for future use in PDN therapy, including Nav 1.7 antagonists, N-type calcium channel blockers, NGF antibodies and angiotensin II type 2 receptor antagonists.
Introduction
Peripheral neuropathy is characterized by diffuse damage to the peripheral nerve fibres. The commonest cause of peripheral neuropathy is diabetes, and 30-90% of patients with diabetes have peripheral neuropathy [Callaghan et al. 2012a ]. Diabetic sensorimotor polyneuropathy (DSPN), the most common type of diabetic neuropathy, is associated with an impaired quality of life, significant morbidity and increased healthcare costs. Additionally, 16-34% of patients with diabetes report painful neuropathic symptoms and the prevalence is greater in type 2 diabetes, women and South Asians [Ziegler et al. 2009; Abbott et al. 2011] . The symptoms of painful diabetic neuropathy (PDN) can be debilitating and can cause sleep disturbances, anxiety and interfere with physical functioning [Galer et al. 2000 ].
PDN represents an ongoing therapeutic challenge for patients and caregivers and it is thought that as many 39% of cases of PDN may be untreated [Daousi et al. 2004] . Guidelines have been developed by professional organizations to provide a rational approach to the treatment of PDN [Spallone, 2012] . In this review, we seek to evaluate the main therapeutic approaches for PDN and provide insights into future management options.
Assessment and diagnosis
The diagnosis of PDN is primarily clinical, based on a history of neuropathic pain and confirmatory examination findings, establishing deficits associated with neuropathy. Although one might argue that confirming neuropathy using tests which assess large fibre deficits (loss of sensation, monofilament exam, reflexes) are not relevant to painful symptoms which are driven principally by small fibre damage. Patients report intermittent or continuous symptoms of pain described as burning, stabbing, tingling, numb, hot, cold or itching in a distal-to-proximal 'glove-and-stocking' distribution, usually beginning in the feet. The pain is typically symmetrical and worsens at night. Abnormal sensory perception, such as reduced or heightened perception of hot, cold, touch or pin-prick sensation, or allodynia, may be present on examination [Callaghan et al. 2012a] .
Neuropathic pain scales have been devised to aid diagnosis and these may also provide insight into the severity of the patient's symptoms [Papanas and Ziegler, 2011] . The Michigan Neuropathy Screening Instrument (MNSI) and Neuropathy Disability Score (NDS) are designed to assess neuropathic impairment and can act as screening tools for DSPN [Feldman et al. 1994; Weintrob et al. 2007 ]. The severity of pain in PDN can be assessed through pain scores such as the Brief Pain Inventory and the Neuropathic Pain Questionnaire (NPQ) [Cleeland and Ryan, 1994; Krause and Backonja, 2003] . The NPQ can also be used to follow up patients along with the Neuropathic Pain Symptom Inventory, a 10-item questionnaire to quantify and evaluate symptoms of neuropathic pain [Kelly et al. 2005] . In addition, the quality of life can be assessed through neuropathy-specific quality of life scores such as the Neuro-QoL [Cella et al. 2012 ].
Due to the subjective nature of the symptoms reported by patients, these scales may not produce consistent results and may lack the sensitivity to track any objective changes in neuropathy status, partly because these scales assess pain status and are thus subjective, measuring largely positive symptoms [Dyck et al. 2007 ]. In comparison, measures of the severity of neuropathy typically focus on negative signs and symptoms. Quantitative sensory testing (QST) has been used in clinical trials to measure progression of neuropathy. However, PDN is principally caused by small-nerve fibres, which are not assessed using the standard QST of vibration perception [Shy et al. 2003; Tavakoli et al. 2008] . Recent guidance has clearly stipulated that QSTs should not be used as standalone tests for the diagnosis of neuropathic pain [Backonja et al. 2013] . Although, skin biopsies which measure intraepidermal nerve fibre density have been used to diagnose and assess neuropathy [Bakkers et al. 2014 ] and corneal confocal microscopy has been proposed as a reliable, noninvasive marker of neuropathy that may be used to objectively assess neuropathy in PDN [Shy et al. 2003 ].
Treatments for diabetes mellitus
Upon the finding of peripheral neuropathy in a patient, other potential causes of neuropathy must be excluded. Once the diagnosis of PDN is established, there are two therapeutic approaches: pathogenetic treatments target the underlying pathophysiological processes to prevent nerve fibre loss, and symptomatic treatments aim to alleviate the painful symptoms of PDN to normalize physical and psychological functioning.
Pathogenetic treatments
A number of pathogenetic treatments have been evaluated in PDN ( Figure 1) . A relationship between chronic hyperglycaemia and diabetic neuropathy has been established in several observational studies [Tesfaye et al. 1996; Herman et al. 1998; Oyibo et al. 2002] . It is thought that prevention of diabetic neuropathy would also help arrest the development of PDN, although there are contradictory data on the association between hyperglycaemia and PDN [Sorensen et al. 2002; Chong and Hester, 2007] .
Glucose control. Data from the Diabetes Control and Complications Trial (DCCT) emphasized a role for intensive glucose control through insulin in both the primary and secondary prevention of PDN in patients with type 1 diabetes. The prevalence of DSPN remained lower in the intensive insulin therapy group of the DCCT many years after the initial intervention in what has been termed a memory effect [The Diabetes Control and Complications Trial Research Group, 1993] . Similarly, the Epidemiology of Diabetes Interventions and Complications study demonstrated a reduced incidence of neuropathy in patients with type 1 diabetes receiving intensive insulin therapy [Albers et al. 2010 ].
In patients with type 2 diabetes, the role of intensified glycaemic control in preventing and managing DSPN is less clear with studies offering contradictory conclusions. A recent meta-analysis of randomized control trials found no significant benefit of intensive glycaemic control in reducing the incidence of DSPN in patients with type 2 diabetes [Boussageon et al. 2011 ]. This conclusion was supported by a Cochrane review which demonstrated no significant improvement in markers of neuropathy in patients with type 2 diabetes managed through intensive glycaemic control [Callaghan et al. 2012b] . However, most studies conducted in patients with type 2 diabetes were not specifically designed to investigate the effect of intensive glycaemic control on DSPN and thus only incorporated a rudimentary assessment of neuropathy.
Pancreas transplantation. The only known therapy to restore insulin secretion in response to feedback mechanisms in patients with diabetes is pancreas transplantation. It has been suggested that the reversal of neuropathy takes around 10 years after transplantation [Fioretto et al. 1998 ]. Neurophysiological examination at 3 months and 1 year in a series with 26 patients noted improvements in action potential amplitude and conduction velocity following transplantation [Agudo et al. 2002] . However, another study that followed up 61 patients with type 1 diabetes after pancreas transplantation found an improvement in motor and sensory function but nerve conduction velocity and autonomic function was unaffected at 10-year follow up [Kennedy et al. 1990; Navarro et al. 1997 ]. These findings were confirmed by a subsequent study. A study of 18 patients found no improvement in intraepidermal nerve fibre density (IENFD) on skin biopsy in 15 patients, with only 3 patients showing an increase in IENFD after kidney and pancreas transplantation. It has been suggested that in some patients DSPN may reach a nonreversible stage [Boucek et al. 2008 ]. However, any improvement in neuropathy depends entirely on the endpoint chosen to assess efficacy. Thus in a recent study whilst there was no change in electrophysiology, QST and IENFD, there was a significant corneal nerve regeneration in 15 patients, 6 months after transplantation [Mehra et al. 2007 ].
The role of pancreas transplantation in the management of DSPN is limited by the availability of suitable organs, the complications of surgery and the consequences of long-term immunosuppression. Islet-cell transplantation is being considered as a less invasive option in patients with type 1 diabetes and marked improvements in neurophysiology have been reported in these patients, although skin biopsy results showed no improvement [Del Carro et al. 2007 ].
α-Lipoic acid. An increased free-radical production along with defective antioxidant mechanisms can generate oxidative stress that has been linked to the development of DSPN [Vincent et al. 2011] . α-Lipoic acid (ALA) is an antioxidant that has been licensed to treat symptomatic DSPN in Germany [Chong and Hester, 2007] . ALA has been found to be well tolerated, however it must be delivered intravenously for symptom relief. Indeed a meta-analysis of four placebo-controlled trials by Ziegler and colleagues found a clinically meaningful improvement in the symptoms of DSPN after administration of 600 mg/day of ALA over 3 weeks [Ziegler et al. 2004 ]. However, it should be noted that a placebo-controlled, randomized, double-blind trial reported no improvement in neuropathy after 4 years of treatment with ALA as assessed using neurophysiology, quantitative sensory testing and a composite neuropathy score. The results of this trial should be interpreted with caution as no worsening in neuropathy was reported in the placebo arm of the study, which may have important implications for study design [Dyck et al. 2007 ]. Aldose reductase inhibitors. Aldose reductase is an important enzyme in the polyol pathway involved in the metabolism of blood glucose [Oates, 2002] . Thus, aldose reductase inhibitors (ARIs) have been proposed to prevent DSPN. A number of ARIs have been tested but most have been found to have significant adverse effects and limited efficacy [Boulton et al. 2013 ]. The ARI epalrestat has been found to improve patientreported neuropathic symptoms with an acceptable safety profile, and a 3-year randomized trial suggested a preventative role for DSPN with epalrestat [Goto et al. 1995; Hotta et al. 2006 ].
Benfotiamine. Benfotiamine, a fat-soluble analogue of thiamine/vitamin B1, has been shown in animal models to inhibit three different pathways involved in vascular damage in diabetes [Hammes et al. 2003 ]. In a phase III placebo-controlled trial involving 165 patients treated with benfotiamine for 6 weeks, improvement was seen in the primary outcome measure (Neuropathy Symptom Score) in the per-protocol arm compared with placebo, although no improvement was found in the intent-to-treat arm of the study. In contrast, another placebo-controlled study in a population with diabetes found no significant differences between the treatment and placebo arms in peripheral nerve function and soluble inflammatory markers. It should be noted, however, that DSPN was not evident in all of the patients at initial assessment [Stracke et al. 2008 ].
Other treatments. C-peptide, a 31-amino acid component of proinsulin, has been suggested to reverse the structural and functional changes due to diabetes in rats and humans. It does so by stimulating Na + /K + ATPase and through activation of various transcription factors [Cotter et al. 2003; Kamiya et al. 2004 ]. C-peptide therapy in 139 human subjects in a double-blind, randomized, placebo-controlled trial was found to improve sensory function in patients with type 1 diabetes and mild neuropathy [Cotter et al. 2003 ].
In a placebo-controlled study, the angiotensin-converting enzyme (ACE) inhibitor trandolapril has been reported to improve the neurophysiological indices of neuropathy at 12 months, even in patients who are normotensive with mild diabetic neuropathy [Malik et al. 1998 ]. Furthermore, in a larger randomized trial (DEMAND study) the calcium channel blocker manidipine and ACE inhibitor delapril in combination, or Delapril on its own significantly reduced the progression of neuropathy compared with placebo. Hyperlipidaemia has been implicated in the pathogenesis of diabetic neuropathy and it has been suggested that adequate control of blood lipid levels through lipid-lowering agents may prevent or ameliorate the effects of DSPN [Fried et al. 2001] . Additionally, HMG-coenzyme A reductase inhibitors (statins) have been suggested to have additional neuroprotective effects [Leiter, 2005] . Elevated triglycerides have been shown to correlate with the loss of myelinated fibre density, independent of diabetes duration and glycaemic control [Wiggin et al. 2009 ] and are also an independent risk factor for amputation in patients with diabetes ]. An improvement in diet and exercise with an improvement in triglycerides has been shown to result in an increase in IENFD in subjects with IGT [Smith et al. 2006] and fenofibrate has been shown to significantly reduce amputations in the FIELD study [Malik et al. 2013; Rajamani et al. 2009 ].
Symptomatic treatment
The symptomatic management of neuropathic pain in diabetes remains a major management challenge for clinicians and a number of clinical guidelines have evolved to guide clinicians as to the most effective treatments for these patients. Safety and efficacy is usually compared for pain relief medication in PDN through numbers needed to treat (NNTs) or numbers needed to harm to achieve 30% or 50% pain relief. The choice of first-line and second-line agents differs between guidelines due to intrinsic methodological differences in the criteria employed to define efficacy. However, most guidelines suggest usually using tricyclic agents (TCAs), serotonin-norepinephrine reuptake inhibitors (SNRIs) or γ-aminobutyric acid (GABA) analogues (gabapentin or pregabalin) as first-line agents followed by opioids and topical treatments [Spallone, 2012] .
Nonsteroidal anti-inflammatory drugs (NSAIDs) are often prescribed for short-term analgesia, primarily when the diagnosis is deemed not to be PDN. However, they have been found to be effective compared with placebo in an 18-patient placebo-controlled study, but their use has not been extensively evaluated, due to their potential to cause gastrointestinal haemorrhage or to exacerbate preexisting renal dysfunction in diabetes [Cohen and Harris, 1987] . TCAs, SNRIs and GABA analogues are commonly used for the treatment of PDN. The major drugs in this category are compared in Table  1 and their sites of action are considered in Figure 2 .
Tricyclic agents. The TCAs have multimodal actions. These include blocking of serotonin and noradrenaline reuptake from synaptic clefts and varying degrees of anticholinergic receptor inhibition. Some agents, such as amitriptyline, have also been found to have a role in sodium channel blockade [Chong and Hester, 2007] . Data on the efficacy of TCAs in the treatment of neuropathic pain are limited and studies usually do not accurately phenotype patients or apply accepted measures of pain relief.
Amitriptyline, desipramine and imipramine have been studied in PDN and have shown efficacy. In a crossover study of 29 patients, amitriptyline prescribed at an average dose of 90 mg daily was [Hollingshead et al. 2006; Saarto and Wiffen, 2007; Derry et al. 2009; Lunn et al. 2009; Moore et al. 2009a Moore et al. , 2011 Attal et al. 2010; Dworkin et al. 2010; Bril et al. 2011; Spallone, 2012] . found to be superior to placebo in managing diabetic neuropathic pain, even in patients without depression [Max et al. 1992] . A crossover study of desipramine in 20 subjects favoured active treatment over placebo [Max et al. 1991] . Additionally, three randomized controlled trials of imipramine have all favoured treatment over placebo for the management of PDN [Kvinesdal et al. 1984; Sindrup et al. 1989 Sindrup et al. , 1990 . However, TCAs are associated with a high side-effect burden which may limit their use in patients with diabetes. In a meta-analysis of the efficacy and safety of six antidepressants and GABA analogues for the management of PDN, amitriptyline was found to be the least safe agent for this indication [Rudroju et al. 2013] . In clinical practice, the high doses used in the clinical trials are rarely used due to side effects and therefore lower doses are prescribed.
Serotonin-norepinephrine reuptake inhibitors. The SNRI duloxetine was the first drug to be approved for DPN by the US Food and Drug Administration in 2004 based on data from large randomized controlled trials [Tavakoli et al. 2008 ]. In the first placebo-controlled doubleblind trial, patients treated with duloxetine at 60 mg and 120 mg reported significant improvement in average pain scores continuing throughout the study [Goldstein et al. 2005] . These findings are supported by a recent Cochrane Collaboration review that analysed data from eight studies, including 2728 participants, and concluded that 60 mg and 120 mg daily doses of duloxetine were efficacious in the management of PDN, but lower doses were not associated with improvement. Minor side effects were commonly present and occurred more frequently with higher doses but major side effects were rare [Lunn et al. 2014 ]. Somnolence and constipation were reported in 20% and 14% of patients receiving 60 mg daily duloxetine [Goldstein et al. 2005 ]. In the UK, duloxetine has been found to be a cost-effective agent for PDN [Beard et al. 2008] and was indeed endorsed by NICE (Clinical Guideline 173) in November 2013.
Venlafaxine is another SNRI that has been studied in patients with PDN. In one large placebocontrolled study, venlafaxine produced a greater symptomatic improvement in PDN compared with placebo. However, clinically important electrocardiogram changes were found in seven patients in the treatment arm. Venlafaxine only showed benefit in this study at doses exceeding 150 mg per day. Below this dose, venlafaxine only affects serotonergic transmission and does not act as an SNRI [Rowbotham et al. 2004] .
Carboxamides, GABA analogues and other historical anticonvulsants. Carbamazepine was among the first of the carboxamides to be studied for managing PDN and works by primarily blocking voltage-sensitive sodium channels to lower peripheral nerve excitability. Two small placebocontrolled studies have suggested that carbamazepine may be useful in controlling neuropathic pain [Rull et al. 1969; Wilton, 1974] . However, its adverse effects include bone marrow suppression and osteoporosis and thus it has been superseded by other agents [Chong and Hester, 2007] .
Oxcarbazepine, a keto-analogue of carbamazepine, has also been studied in PDN. One multicentre trial reported a statistically significant reduction in its primary endpoint of pain score assessed through a visual analogue scale (VAS) [Dogra et al. 2005 ]. However, two subsequent trials did not corroborate these findings and found no difference in VAS score from baseline measurements during these trials [Beydoun et al. 2006; Grosskopf et al. 2006 ].
Gabapentin mimics the actions of the neurotransmitter GABA, though its actions in relieving pain are thought to be due to inhibition of the α 2 δ unit of the calcium channel. It is now widely recommended in guidelines for the treatment of PDN [Spallone, 2012] . In one placebo-controlled trial involving 165 patients, the NNT to achieve 50% pain relief was calculated to be 3.7 [Backonja et al. 1998 ]. A systematic review of 35 studies concluded that gabapentin was effective in managing neuropathic pain and a recent analysis of the efficacy of six agents for managing PDN found gabapentin to offer the most favourable balance between safety and efficacy [Mellegers et al. 2001; Rudroju et al. 2013] .
Pregabalin is a higher potency gabapentinoid with a similar mechanism of action to gabapentin. Four double-blind placebo-controlled trials have reported an improvement in pain scores following pregabalin therapy. A dose-dependent response in reduction of sleep interference and speed of onset of relief has been reported and a dose of 600 mg daily was associated with the greatest effect. However a number of side effects including mood disturbance, ankle oedema and sedation have been reported [Lesser et al. 2004; Rosenstock et al. 2004; Richter et al. 2005; Arezzo et al. 2008] . Abrupt discontinuation of pregabalin can be associated with cerebral oedema and encephalopathy. It remains one of the few drugs licensed in both the USA and the UK for the treatment of PDN [Tavakoli et al. 2008] . A recent Spanish cost-comparative analysis of adding pregabalin or gabapentin therapy to patients with PDN who were community treated found that pregabalin therapy generated lower total healthcare costs compared with gabapentin [Sicras et al. 2013] .
Another antiepileptic agent, lamotrigine, has been studied in patients with PDN. However, inconsistent results in pain relief have been reported, and a recent Cochrane review, which considered four trials of lamotrigine in PDN, did not find any convincing evidence for the use of lamotrigine in PDN [Eisenberg et al. 2001; Wiffen et al. 2013] .
Topiramate was shown in a large placebo-controlled trial to be efficacious in the symptomatic management of neuropathic pain in diabetes [Raskin et al. 2004 ]. This beneficial effect was maintained in the open-label extension of the study [Donofrio et al. 2005 ]. However, three smaller studies found no significant change in pain relief in PDN with topiramate [Thienel et al. 2004] .
N-methyl-D-aspartate receptor antagonist. N-methyl-D-aspartate receptor antagonists are generally used for the management of postoperative pain. Dextromethorphan has been found to be effective in alleviating the painful symptoms of diabetic neuropathy when used on its own or in combination with memantine [Sang et al. 2002] . More recently, dextromethorphan coadministered with quinidine was found to be effective on all six pain rating scales used in a multicentre, double-blind, placebo-controlled trial that randomized 379 patients with DPN [Shaibani et al. 2012 ]. These findings confirmed the results of a smaller openlabel study [Thisted et al. 2006 ].
Recently, a randomized double-blind placebocontrolled trial investigated the role of a topical 5% ketamine cream for the management of DPN and showed that it was no more effective than placebo for pain relief in these patients [Mahoney et al. 2012] .
Opioid analgesia. Although primarily a µ-opioid receptor agonist, tramadol has also been suggested to effect descending inhibitory pathways, modulating nociception [Chong and Hester, 2007] . One multicentre, double-blind, placebocontrolled study reported that at an average dose of 200 mg per day, tramadol resulted in significant pain relief on a Likert scale and also improved social and physical functioning [Harati et al. 1998 ]. However, adverse effects were reported at higher doses, including nausea (23%), constipation (21%) and headache (17%) [Bril et al. 2011 ]. In 2012, tapentadol extended release (ER) was only the third drug to receive FDA approval for the treatment of neuropathic pain. Tapentadol ER was administered to 588 patients for a 3-week open-label phase, and subsequently, 395 patients with at least a one-point reduction in pain intensity were randomized 1:1 to receive placebo or the optimal fixed dose of tapentadol ER for a 12-week double-blind phase to show a highly significant reduction in pain intensity for those on active treatment [Schwartz et al. 2011 ]. The mechanism of action is thought to be via opioid spinal-supraspinal synergy, as well as intrinsic spinally mediated μ-opioid receptor agonist-norepinephrine reuptake inhibitor effect [Christoph et al. 2013] . The other opioid that has been studied in PDN is oxycodone, which has higher bioavailability and potency compared with morphine and a reduced side-effect profile. One study involving 159 patients reported a reduction in pain intensity on VAS using 20 mg controlled release oxycodone [Gimbel et al. 2003 ]. A placebo-controlled crossover study of 36 patients reported a reduction in daily pain scores in patients randomized to the oxycodone arm of the study [Watson et al. 2003 ].
However, the use of opioids for the management of PDN remains controversial as most trials conducted have been small in both sample size and duration, and have not established risk-benefit ratios. Long-term adverse effects of opioid dependency and abuse, constipation, itching, and changes in immunological functioning and suppression of the pituitary axis may limit the use of opioid analgesics and increase costs associated with monitoring use [Brennan, 2013] . Additionally, the risk of aberrant opioid use should be evaluated prior to prescribing opioid through the use of a validated screening method, such as the Opioid Risk Tool or the Diagnosis, Intractability, Risk, Efficacy score [Moore et al. 2009b ].
Other treatments. Capsaicin is an alkaloid derived from red chilli peppers and topical application has been found to be effective in PDN [Zhang et al. 1994 ]. The Capsaicin Study Group found significant improvements in pain relief and a decrease in pain intensity in a double-blind placebo-controlled trial of 277 patients [The Capsaicin Study Group, 1991] . However, the demonstration of epidermal denervation in patients treated with capsaicin with impaired subsequent nerve regeneration in subjects with diabetes [Polydefkis et al. 2004] cautions the use of this therapy, especially in patients with established neuropathy.
A randomized, placebo-controlled trial demonstrated a nonsignificant trend towards reduction in foot pain in patients treated with a 0.1% topical clonidine gel compared with placebo [Campbell et al. 2012 ]. However, this study reported a significant reduction in pain scores in patients with functional and possibly sensitized nociceptors (assessed through pain to topical capsaicin application) in the affected skin receiving topical clonidine therapy.
An isosorbide dinitrate spray has been found to reduce pain in diabetic neuropathy by 18% as evaluated through VAS in a short-term placebocontrolled trial. Some guidelines suggest that its use should be considered in patients with PDN [Bril et al. 2011; Spallone, 2012] .
A small open-label, 3-week study of 56 patients with DPN showed that up to four 5% lidocaine patches used for up to 18 h/day significantly improve pain and quality-of-life ratings, and allowed tapering of concomitant analgesic therapy [Barbano et al. 2004 ].
It has been suggested that botulinum toxin type A may provide relief of neuropathic pain in diabetes through its modulatory effects on afferent sensory fibre firing. Indeed, a double-blind crossover trial of intradermal botulinum toxin type A in 18 patients with PDN demonstrated a significant reduction in pain and improvement in sleep quality [Yuan et al. 2009] . Botulinum toxin type A may represent a novel approach to treatment in PDN but the results of this trial need to be verified in larger studies with longer periods of observation.
Nonpharmacological approaches
Patient education is considered essential to promote glycaemic control and help avoid the late complications of diabetic neuropathy [Bril, 2012] .
Some patients with PDN may not achieve adequate relief with conventional therapy or may suffer from adverse effects of the prescribed treatments [Bril et al. 2011 ]. Nonpharmacological approaches have been proposed for these patients.
Various forms of electrical stimulation have been used to manage pain in diabetic neuropathy, including transcutaneous electrical nerve stimulation, percutaneous electrical nerve stimulation and frequency-modulated electromagnetic neural stimulation [Bril et al. 2011] . A recent review analysed eight studies that evaluated the use of electrical stimulation in PDN. Six of these studies found significant pain relief in patients treated with electrical stimulation compared with placebo or sham treatment, suggesting a likely role for treating diabetic neuropathic pain [Thakral et al. 2013] .
A single-blind placebo-controlled randomized trial to evaluate the use of acupuncture in PDN in 45 subjects recently reported an improvement in the outcome measures used to assess pain in the acupuncture arm relative to sham treatment [Garrow et al. 2014 ]. However, Chen and colleagues suggest that it is difficult to draw meaningful conclusions from acupuncture trials in diabetic neuropathy as trials often have flawed study design and avoid the use of the robust outcome measure of pain in diabetic neuropathy [Chen et al. 2013] .
Future directions
It is evident from the broad range of drugs that have been evaluated in PDN that there is no consensus about a single most effective drug, and monotherapy rarely provides adequate pain relief. Additionally, most studies compare therapies against placebo or sham treatment and there is a need for comparative studies between different pharmacological agents. In a small study of 56 patients with DPN or postherpetic neuralgia (PHN) randomized in a 1:1:1 ratio to receive one of three sequences of daily oral gabapentin, nortriptyline, or their combination, the combination was more efficacious than either drug given alone. Therefore, it was recommend that a combination may be considered in patients who show a partial response to either drug given alone but who seek additional pain relief [Gilron et al. 2009 ]. Bansal and colleagues recently reported in a head-to-head study that pregabalin may be more efficacious than amitriptyline in patients with PDN [Bansal et al. 2009 ]. In a multicentre, double-blind, parallelgroup study of 805 patients with DPN in the initial 8-week therapy 60 mg/day duloxetine was found to be superior to 300 mg/day pregabalin (p < 0.001) and subsequently a 50% response rate for pain relief was shown in 52.1% for combination and 39.3% for high-dose monotherapy (p = 0.068) ]. Gilron and colleagues reported that a combination of morphine and gabapentin had superior efficacy in the treatment of neuropathic pain with a similar frequency of adverse effects compared with monotherapy with morphine or gabapentin at maximal tolerated doses [Gilron et al. 2005] . A number of target sites have been proposed for the treatment of PDN [Vincent et al. 2011] . Manipulation of the temperature-sensitive transient receptor potential (TRP) channel on nociceptive neurons has been proposed as an attractive strategy in targeting the pain pathway, especially since TRPV1 desensitization by topical agonists such as capsaicin has been in use for PDN [Brederson et al. 2013] .
Targeting growth factors involved in the pathogenesis of diabetic neuropathy remains an option for future pharmacological therapies. The therapeutic potential of vascular growth factors, particularly vascular endothelial growth factor (VEGF), is considerable, however there has been limited clinical translation in this area and indeed a recent clinical trial of VEGF was stopped due to futility [Verheyen et al. 2013 ].
Mutations in the Nav1.7 sodium channel have been described in some patients with peripheral neuropathy [Galloway and Chattopadhyay, 2013] . Nav1.7 antagonists are currently in development. Xenon402, a novel Nav1.7 blocker, was found to be effective in erythromelalgia and it has been suggested that Nav1.7 blockers may be useful in other types of neuropathic pain [McGowan et al. 2009; Goldberg et al. 2012] .
Small molecule angiotensin II type 2 receptor (AT 2 R) antagonists have also been proposed as analgesics for neuropathic pain [Smith et al. 2013] . Most recently, a high-profile double-blind placebo-controlled trial demonstrated the efficacy of EMA401, a novel AT 2 R antagonist, in the treatment of PHN and this drug remains in development as a therapeutic agent for neuropathic pain [Rice et al. 2014 ].
α-Conotoxins selective for GABA(B) receptor dependent inhibition of N-type Ca(2+) channels have been shown to relieve allodynia in experimental models [Klimis et al. 2011 ] and of course ziconotide has been approved for severe refractory pain by the FDA since 2004, but the major limitation is the intrathecal mode of administration [Sanford, 2013] . Z160 is currently in phase II clinical trials for a number of pain indications, including PHN and radicular pain.
Conclusion
PDN is common and is associated with significant impairment in the quality of life of patients with diabetes. Despite its high burden, it remains underdiagnosed and undertreated. Treatment which repairs nerves has yet to be found and translated into clinical trials and eventually approved therapy in clinical practice. Whilst a number of treatment options exist and various guidelines and algorithms have been formulated, none are satisfactory. Various symptomatic treatments have been proposed to manage neuropathic pain but few have been found to be effective, with only three medications currently FDA approved for PDN. Future research must establish the most efficacious drug combinations and in addition exploit new mechanisms and investigate new drugs for the treatment of pain in diabetic neuropathy. Donofrio, P., Raskin, P., Rosenthal, N., Hewitt, D., Jordan, D., Xiang, J. et al. (2005) Safety and effectiveness of topiramate for the management of painful diabetic peripheral neuropathy in an openlabel extension study. Clin Ther 27: 1420-1431.
